Pharmacology News and Research

Latest Pharmacology News and Research

NexMed's NexACT technology enhances Taxol's bioavailability through oral administration

NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from its research and development group at Bio-Quant successfully demonstrated the ability of the NexACT technology to deliver an oral formulation of Taxol® (paclitaxel) and to enhance the drug’s bioavailability by approximately ten-fold through this oral administration. Taxol, a first line chemotherapy drug used to treat breast, lung and ovarian cancers, is currently administered through an intravenous infusion that can take up to 24 hours to complete.

13 Jan 2010

First sulfite-free rectal suspension for UC

sfRowasa™ (mesalamine) Rectal Suspension 4g/60mL –Sulfite-Free Formulation, is the first sulfite-free rectal suspension available for Ulcerative colitis (UC). According to a study published in The American Journal of Gastroenterology, products containing sulfites may exacerbate natural sulfide levels in the colon and may increase inflammation in UC patients. With its sulfite-free preparation, sfRowasa™ offers a new treatment option for the treatment of active, mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis.

13 Jan 2010

FDA, Biovista to collaborate in analysis of drug side effects

Biovista Inc. today announced that the U.S. Food and Drug Administration (FDA) has licensed its technology platform to help analyze, identify, and better understand the way certain drugs can cause harmful side effects.

13 Jan 2010

Bevacizumab drug shows promise to slow tumor growth in lung cancer patients

Phase II study results of the agent ASA404 showed promise in patients with either squamous or non-squamous non-small cell lung cancer (NSCLC).

13 Jan 2010

Abe's Garden raises $3.5M to include a facility to care for adults with Alzheimer's disease

Abe's Garden, a non-profit organization that seeks to establish a national model of residential living and daycare programs for those suffering with Alzheimer's disease, has raised $3.5 million toward its $9 million capital campaign announced today.

12 Jan 2010

Pharmaron Holdings acquires Bridge Laboratories China

Pharmaron Holdings Limited, today announced it completed the acquisition of Bridge Laboratories China. Bridge Laboratories China is the leading contract research organization (CRO) in China providing western standard GLP-compliant toxicology services to pharmaceutical and biotech companies from around the world. With this acquisition, Pharmaron becomes the first integrated CRO in China supporting clients with drug discovery and development processes in support of IND filings. This strategic acquisition strengthens Pharmaron's leading position in the fast-growing, highly dynamic pharmaceutical CRO industry.

12 Jan 2010

Lives of 400 Swedes can be saved annually if side effects of pharmaceuticals prevented

A scientific study indicates that the lives of 400 Swedes could be saved annually if measures were taken to prevent side effects of pharmaceuticals. Now these researchers in Sweden, at the Nordic School of Public Health (NHV) and elsewhere, have reviewed randomly selected deaths in three Swedish counties and found that 14 percent of these deaths could have been avoided if a drug had been replaced or if the dosage had been lowered.

11 Jan 2010

Institut Curie, Ipsogen sign scientific collaboration agreement in breast cancer domain

The INSTITUT CURIE and IPSOGEN (FR0010626028 - ALIPS) announce the signing of a scientific collaboration agreement in the breast cancer domain. Within the framework of this project, the current scientific knowledge on Ipsogen's MapQuant Dx Grade Genomic, HER2 and HR tests will be increased thanks to new data established from a large population of patients treated at the Institut Curie.

11 Jan 2010

Gene therapy may help correct molecular flaws that cause brain disease

Neuroscientists have forged an unlikely molecular union as part of their fight against diseases of the brain and nervous system.

9 Jan 2010

Scientific societies to hold Experimental Biology 2010 meeting

Six scientific societies announced they will hold their annual meeting, Experimental Biology (EB 2010; www.experimentalbiology.org), April 24-28, 2010 in Anaheim, CA. The societies are the American Association of Anatomists (AAA), American Physiological Society (APS), American Society for Biochemistry and Molecular Biology (ASBMB), American Society for Investigative Pathology (ASIP), American Society for Nutrition (ASN) and American Society for Pharmacology and Experimental Therapeutics (ASPET).

9 Jan 2010

NexMed updates corporate activities

NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today provided an update on ongoing corporate activities and the status of the Company’s NASDAQ listing.

9 Jan 2010

LAB Research completes research and development program that involves pulmonary monitoring system

LAB Research Inc. ("LAB" or "LAB Research"),a Canadian-based global non-clinical contract research organization, today announced that it recently completed a research and development program that involves real time quantitative pulmonary monitoring of non-human primates using wireless telemetry technology.

8 Jan 2010

Kyowa Hakko Kirin receives exclusive rights to develop and commercialize bardoxolone methyl

Reata Pharmaceuticals, Inc. (Reata) and Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) announced today that they have entered into a licensing agreement that provides Kyowa Hakko Kirin with the exclusive rights to develop and commercialize Reata’s lead compound, bardoxolone methyl (bardoxolone), in Japan and other selected Asian markets.

8 Jan 2010

UV LED therapy can be used for treating focal epilepsy in humans

Researchers from the University of Minnesota Medical School discovered that light from an ultraviolet diode (UV LED) reduced "seizure-like" activity in a rat epilepsy model. During the study, UV light released gamma aminobutyric acid (GABA) from the "caged" compound carbonyl amino butanoic acid (BC204).

7 Jan 2010

Pharsight releases Phoenix NLME and Phoenix Connect

Pharsight, a market-leading provider of software and scientific services to improve productivity and decision-making in clinical drug development, today announced that it has released two new data analysis tools; Phoenix NLME and Phoenix Connect.

6 Jan 2010

Study reveals molecular mechanism that could lead to new approach in treating obesity

Mayo researchers collaborating with investigators at the University of Iowa, University of Connecticut and New York University (NYU) have discovered a molecular mechanism that controls energy expenditure in muscles and helps determine body weight. Researchers say this could lead to a new medical approach in treating obesity.

5 Jan 2010

Bacterial enzyme decreases cocaine desire

A recent study shows that a bacterial protein may help cocaine addicts break the habit.

3 Jan 2010

UB neurobiologist studies the impact of acute and chronic caffeine consumption in young people

Caffeine is a stimulant drug, although legal, and adults use it widely to perk themselves up: Being "addicted" to caffeine is considered perfectly normal.

30 Dec 2009

Small molecules reverse protein trafficking and mitochondrial dysfunction in Parkinson's disease models

Parkinson's disease is a neurodegenerative disorder characterized by tremors, muscle rigidity, and slowed movements. There is currently no cure for the disease, and current Parkinson's therapies only address disease symptoms, not the disease's cellular cause.

29 Dec 2009

MDRNA closes $1M bridge loan

MDRNA, Inc., a leading RNAi-based drug discovery and development company, today announced the closing of a bridge loan pursuant to a Note and Warrant Purchase Agreement. Under the terms of the loan, the Company sold promissory notes in the aggregate principal amount of $1.0 million and issued warrants to purchase an aggregate of approximately 1.1 million shares of the Company's common stock at $1.02 per share to certain accredited investors.

24 Dec 2009

Pharmacology News and Research

Latest Pharmacology News and Research

NexMed's NexACT technology enhances Taxol's bioavailability through oral administration

First sulfite-free rectal suspension for UC

FDA, Biovista to collaborate in analysis of drug side effects

Bevacizumab drug shows promise to slow tumor growth in lung cancer patients

Abe's Garden raises $3.5M to include a facility to care for adults with Alzheimer's disease

Pharmaron Holdings acquires Bridge Laboratories China

Lives of 400 Swedes can be saved annually if side effects of pharmaceuticals prevented

Institut Curie, Ipsogen sign scientific collaboration agreement in breast cancer domain

Gene therapy may help correct molecular flaws that cause brain disease

Scientific societies to hold Experimental Biology 2010 meeting

NexMed updates corporate activities

LAB Research completes research and development program that involves pulmonary monitoring system

Kyowa Hakko Kirin receives exclusive rights to develop and commercialize bardoxolone methyl

UV LED therapy can be used for treating focal epilepsy in humans

Pharsight releases Phoenix NLME and Phoenix Connect

Study reveals molecular mechanism that could lead to new approach in treating obesity

Bacterial enzyme decreases cocaine desire

UB neurobiologist studies the impact of acute and chronic caffeine consumption in young people

Small molecules reverse protein trafficking and mitochondrial dysfunction in Parkinson's disease models

MDRNA closes $1M bridge loan

Industry Focus - Biopharma eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Pharmacology News and Research

Latest Pharmacology News and Research

Industry Focus - Biopharma eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in